Nicoderm. Image from Wikipedia
The Global Transdermal Patch Market is Expected to Reach $20 Billion by 2028 – ResearchAndMarkets.com
DUBLIN-March 16, 2022 – Transdermal patches have been developed as a result of technological breakthroughs in medicine delivery. The active elements of medications are delivered across skin into the systemic blood circulation in a continuous or measured way through diffusion by transdermal skin patches. Transdermal patches have other benefits besides being easy for patients and non-invasive, such as avoiding first-pass digestion and gastric/enzymatic degradation. Transdermal patches are currently being marketed as easy-to-use, convenient, and long-lasting goods. Depending on the therapeutic indication, these patches can be worn for up to seven days.
The positive reception of transdermal patches on the global market has fueled more research and development in this field. In 2019, the US Food and Drug Administration approved Secuado, the first transdermal patch to treat Schizophrenia. In addition, Gedeon Richter UK announced in 2021 that it has been designated as the marketing authorization holder (MAH) for Evra, once-weekly contraception for women of reproductive age and the UK’s only transdermal contraceptive patch. The increasing number of product launches in the global industry will boost the market growth.
The global transdermal patch pipeline is full, indicating a bright future for these patches in the next years. For example, in a non-GLP rabbit pharmacokinetic (PK) and skin irritation research, Starton Therapeutics’ STAR-LLD continuous-delivery transdermal patch containing lenalidomide demonstrated encouraging results. Furthermore, the US FDA has set a March 11, 2022 deadline for the new drug application for Aldarity (donepezil transdermal system) for the treatment of individuals with dementia caused by mild, moderate, or severe Alzheimer’s disease. Aldarity is a donepezil transdermal formulation designed to be used once a week for seven days with continuous adherence. During the forecast period, these developing trends will force the market forward.
Currently, there is no transdermal patch in the vaccination category, indicating that there are many unexplored prospects for pharmaceutical businesses in this field. Several clinical trials are under underway to evaluate new vaccination patches for influenza, HIV, COVID-19, and other diseases. Institut Pasteur Korea (IPK) has signed a research service agreement with Juvic Inc. for the cooperative development of microneedle-based influenza vaccines in the year 2022. This collaboration is expected to speed up the development of a microneedle influenza vaccination patch by combining Juvic’s microneedle production technology with IPK’s vaccine research and development skills. Notably, the microneedle-based vaccine not only significantly lowers pain during immunization but can also be administered at room temperature.
The global transdermal patch market is expected to witness high growth rates which are due to the presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, the high adoption rate of advanced technologies is also expected to impel the growth of the market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.
Key Topics Covered:
1. Introduction to Transdermal Patch
2. Transdermal Patches Classification
3. Mechanism of Transdermal Patch Drug Delivery
4. Global Transdermal Patch Market Outlook
5. Global Transdermal Patch Market Trends by Region
6. Transdermal Patches for Cardiovascular Diseases – Market Availability, Dosage & Price Analysis
7. Opioid Drug Containing Transdermal Patches – Market Availability, Dosage & Price Analysis
8. Transdermal Patch in Hormonal Therapy – Market Availability, Dosage & Price Analysis
9. Transdermal Patches for Neurological Disorders – Market Availability, Dosage & Price Analysis
10. Transdermal Patches for Other Conditions – Market Availability, Dosage & Price Analysis
11. Global Transdermal Patch Clinical Pipeline Overview
12. Global Patch Clinical Pipeline By Company, Indication & Phase
13. Marketed Transdermal Patch Clinical Insight
14. Global Transdermal Patch Market Dynamics
15. Global Transdermal Patch Market Future Outlook 2028
16. Competitive Landscape
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 Luye Pharma
16.21 MINRAD International
16.22 NeurogesX
16.23 Noven Pharmaceuticals
16.24 NuPathe
16.25 Nuvo Research
16.26 Novartis
16.27 Pain Therapeutics
16.28 ProStrakan
16.29 Purdue Pharma
16.30 Sanofi
16.31 Scilex Pharmaceuticals
16.32 Senju Pharmaceutical
16.33 Somerset Pharmaceuticals
16.34 Teikoku Seiyaku
16.35 Therapeutic Discovery Corporation
16.36 Transdermal Delivery Solutions Corp
16.37 UCB
16.38 Xel Pharmaceuticals
16.39 Zosano Pharma
For more information about this report visit https://www.researchandmarkets.com/r/p2jupy
Global Semiconductor Revenue Up 17% YoY in Q3 2024; Automotive Sector Rebound Delayed Samsung ranked…
Indian smartphone market rebounds 20% in Q4 2023
CableTV.com survey finds how Americans decide what to watch on TV
AI Market Expects Surprising 2024 Power Shifts Among Vendors, Futurum Intelligence AI Decision Maker Survey…
Global Smart TV Shipments is Poised to Make a Slow Recovery, According to IDC Needham,…
Over 1 Billion Generative AI (GenAI) Smartphones to be Shipped Cumulatively During CY2024-2027